Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
Fiche publication
Date publication
juin 2023
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel, Dr GRANEL-BROCARD Florence, Pr HARLE Alexandre, Pr MERLIN Jean-Louis, Dr HERVIEU Alice, Dr NARDIN Charlée
Tous les auteurs :
Geoffrois L, Harlé A, Sahki N, Sikanja A, Granel-Brocard F, Hervieu A, Mortier L, Jeudy G, Michel C, Nardin C, Huin-Schohn C, Merlin JL
Lien Pubmed
Résumé
With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at one year is approximately 30% and justify extensive research of predictive biomarkers. If in metastatic disease, the follow-up of circulating tumor DNA (ctDNA) has been demonstrated, its interest in adjuvant setting remains to be precised, especially because of a lower detection rate. Further, the definition of a molecular response could prove useful to personalized treatment.
Mots clés
Adjuvant therapy, Circulating tumor DNA, Immunotherapy, Kinase inhibitors, Melanoma
Référence
BMC Cancer. 2023 06 16;23(1):554